Somatostatin Analogues Use in Other than Endocrine Tumor Indications
暂无分享,去创建一个
[1] M. Vranic,et al. Amelioration of Hypoglycemia Via Somatostatin Receptor Type 2 Antagonism in Recurrently Hypoglycemic Diabetic Rats , 2013, Diabetes.
[2] A. Schally,et al. Targeting triple-negative breast cancer through the somatostatin receptor with the new cytotoxic somatostatin analogue AN-162 [AEZS-124] , 2013, Anti-cancer drugs.
[3] Chengwei Tang,et al. Prevention of Severe Acute Pancreatitis With Octreotide in Obese Patients: A Prospective Multi-Center Randomized Controlled Trial , 2012, Pancreas.
[4] Y. Bentur,et al. Octreotide for the treatment of sulfonylurea poisoning , 2012, Clinical toxicology.
[5] A. Maubon,et al. Lanreotide Autogel 90 mg and lymphorrhea prevention after axillary node dissection in breast cancer: a phase III double blind, randomized, placebo-controlled trial. , 2012, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[6] D. Kokona,et al. Pasireotide (SOM230) protects the retina in animal models of ischemia induced retinopathies. , 2012, Experimental eye research.
[7] D. Goulis,et al. Abstract. Background: Antisurvival Factor Therapy for Prostate Dexamethasone plus Somatostatin-analog Manipulation as Bone Metastasis Microenvironment-targeting Therapy for the Treatment of Castration-resistant Prostate Cancer: a Meta-analysis of Uncontrolled Studies , 2022 .
[8] V. Weinberg,et al. Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study. , 2012, Urologic oncology.
[9] M. Mrkobrada,et al. Meta‐analysis: vasoactive medications for the management of acute variceal bleeds , 2012, Alimentary pharmacology & therapeutics.
[10] J. Kountouras,et al. Combination of diclofenac plus somatostatin in the prevention of post-ERCP pancreatitis: a randomized, double-blind, placebo-controlled trial , 2012, Endoscopy.
[11] T. Whelan,et al. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Shi-yong Li,et al. Somatostatin analogues in advanced hepatocellular carcinoma: An updated systematic review and meta-analysis of randomized controlled trials , 2011, Medical science monitor : international medical journal of experimental and clinical research.
[13] H. Schaible,et al. Differential antiinflammatory and antinociceptive effects of the somatostatin analogs octreotide and pasireotide in a mouse model of immune-mediated arthritis. , 2011, Arthritis and rheumatism.
[14] D. Modan-Moses,et al. Treatment of congenital hyperinsulinism with lanreotide acetate (Somatuline Autogel). , 2011, The Journal of clinical endocrinology and metabolism.
[15] T. Cascino,et al. Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma. , 2011, Neuro-oncology.
[16] C. Schulz,et al. Treatment of unresectable skull base meningiomas with somatostatin analogs. , 2011, Neurosurgical focus.
[17] T. Fukui,et al. Meta-analysis: somatostatin or its long-acting analogue, octreotide, for prophylaxis against post-ERCP pancreatitis , 2010, Journal of Gastroenterology.
[18] K. Gurusamy,et al. Meta-analysis of randomized controlled trials on the effectiveness of somatostatin analogues for pancreatic surgery: a Cochrane review. , 2010, HPB : the official journal of the International Hepato Pancreato Biliary Association.
[19] M. Peeters,et al. Diarrhea and the rationale to use Sandostatin. , 2010, Acta gastro-enterologica Belgica.
[20] P. Rehak,et al. Effect of somatostatin analogue octreotide on pain relief after major abdominal surgery , 2009, European journal of pain.
[21] A. Schally,et al. Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162 , 2009, Peptides.
[22] L. Leibovici,et al. Treatment modalities for Graves' ophthalmopathy: systematic review and metaanalysis. , 2009, The Journal of clinical endocrinology and metabolism.
[23] D. Ma,et al. Paclitaxel-octreotide conjugates in tumor growth inhibition of A549 human non-small cell lung cancer xenografted into nude mice. , 2008, European journal of pharmacology.
[24] A. Kiss,et al. Somatostatin and gabexate for post‐endoscopic retrograde cholangiopancreatography pancreatitis prevention: Meta‐analysis of randomized placebo‐controlled trials , 2007, Journal of gastroenterology and hepatology.
[25] E. Soto-Pedre,et al. Sandostatin LAR for cystoid diabetic macular edema: a 1-year experience. , 2004, Diabetes research and clinical practice.
[26] G. D’Amico,et al. Emergency sclerotherapy versus vasoactive drugs for variceal bleeding in cirrhosis: a Cochrane meta-analysis. , 2003, Gastroenterology.
[27] M. Grant,et al. Somatostatin analogues as drug therapies for retinopathies. , 2002, Drugs of today.
[28] I. Shrier,et al. Systematic review: the use of somatostatin or octreotide in refractory diarrhoea , 2001, Alimentary pharmacology & therapeutics.
[29] M. Yaron,et al. A pilot study of a long acting somatostatin analogue for the treatment of refractory rheumatoid arthritis. , 2001, Annals of the rheumatic diseases.
[30] S. H. Wilson,et al. The therapeutic problem of proliferative diabetic retinopathy: targeting somatostatin receptors. , 2001, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[31] A. Bellastella,et al. Somatostatin receptor gene expression and inhibitory effects of octreotide on primary cultures of orbital fibroblasts from Graves' ophthalmopathy. , 2000, Journal of molecular endocrinology.
[32] S. Lamberts,et al. Imaging and medical management of clinically nonfunctioning pituitary tumors , 1995 .